Main takeaway: A decision on Medicare coverage for its Cxbladder project is due next July, and an adverse decision could take years to fight.
The boss of dual-listed cancer diagnostics company Pacific Edge has reiterated that its belt has been “appropriately tightened” for the ongoing Medicare coverage uncertainty it faces in the United States and that it has enough cash for a process that could take years to resolve.
Want to read more? It's easy.
Choose your best value subscription option
Exclusive offer for uni students studying at a New Zealand university (valued at $499).